Ad is loading...
EIVAX
Price
$15.12
Change
+$0.12 (+0.80%)
Updated
Nov 22 closing price
VVIAX
Price
$70.26
Change
+$0.54 (+0.77%)
Updated
Nov 22 closing price
Ad is loading...

EIVAX vs VVIAX

Header iconEIVAX vs VVIAX Comparison
Open Charts EIVAX vs VVIAXBanner chart's image
Allspring Special Large Cap Value A
Price$15.12
Change+$0.12 (+0.80%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$70.26
Change+$0.54 (+0.77%)
VolumeN/A
CapitalizationN/A
EIVAX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
EIVAX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EIVAX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. EIVAX (1.37B). VVIAX pays higher dividends than EIVAX: VVIAX (2.36) vs EIVAX (0.67). EIVAX was incepted earlier than VVIAX: EIVAX (18 years) vs VVIAX (24 years). EIVAX is a more actively managed with annual turnover of: 42.00 vs. VVIAX (10.00). EIVAX has a lower initial minimum investment than VVIAX: EIVAX (1000) vs VVIAX (3000). EIVAX (26.54) and VVIAX (26.09) have marching annual gain over last year. VVIAX return over 5 years is better than : 53.09 vs. EIVAX (10.77).
EIVAXVVIAXEIVAX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence18 years24 years-
Gain YTD20.60019.672105%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets1.37B184B1%
Annual Yield % from dividends0.672.3628%
Returns for 1 year26.5426.09102%
Returns for 3 years-4.6224.77-19%
Returns for 5 years10.7753.0920%
Returns for 10 years8.80112.268%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics